Methandienone is a 17 -alkylated oral steroid that exerts its effects through the androgen receptor. Methandienone acts on the androgen receptor which results in increased protein synthesis and nitrogen retention within muscle cells resulting in dramatic increases in strength and muscle mass.
To rapidly restore muscle tissue atrophied during recovery from a traumatic injury.
To offset muscle catabolism in patients with a wasting syndrome.
To treat certain types of anemia which are non-responsive to first line agents.
Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
Methandienone has been 17 -alkylated to reduce liver clearance making it practical for oral dosing. Methandienone acts directly on androgen receptors resulting in increased nitrogen retention and protein synthesis. Methandienone is subject to aromatization yielding estrogenic side effects if not offset with an aromatase inhibitor. Methandienone metabolism is hepatic with a half-life of 4.5 to 6 hours.
Not indicated for women, children, or the elderly.
Patients with diagnosed or suspected male breast carcinoma or carcinoma of the prostate.
Patients with diagnosed or suspected female breast carcinoma with hypercalcemia as androgenic agents may increaseosteolytic bone resorption.
Women who are pregnant or may become pregnant because of possible masculinization of the fetus.
Patients with nephrosis or the nephrotic phase of nephritis.
Patients with hypercalcemia.
Patients with pre-existing cardiac, renal, and/or hepatic disease.
This product is hepatotoxic and requires Hepatic Monitoring. Discontinue if jaundicing presents.
Elevated liver enzymes and in extreme cases hepatic liver dysfunction may occur. 17-alpha-alkylated androgens may cause cholestatic hepatitis and jaundice, particularly with larger dosages or prolonged treatment. Liver function should be monitored for changes including serum bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (AP).
Edema may be increased in patients on concurrent adrenal cortical steroid or ACTH therapy.
Anabolic steroid hormones may increase low-density lipoproteins (LDL) and decrease high density lipoproteins (HDL). Lipids levels generally return to normal upon discontinuation of treatment.
Anabolic steroids may reduce clotting factors II, V, VII, and X, and may increase pro-thrombin time (PT). Patients should be instructed to report any use of warfarin and any irregular bleeding. Periodic liver function tests should be conducted given the association of 17-alpha-alkylated androgens with hepatotoxicity.
Oral hypoglycemic agents: may inhibit the metabolism of oral hypoglycemic agents which may require adjustment of dosage.
Anticoagulants: Patients on anticoagulants should be carefully monitored during anabolic steroid therapy as anabolic steroids may increase sensitivity to oral anticoagulants. Patients should be monitored regularly during anabolic steroid therapy, particularly during initiation and termination of therapy.
Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.
Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis.
Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anti-coagulant therapy.
Nervous System: Changes in libido, aggression, headache, anxiety, depression, and generalized paresthesia.
Metabolic: reduced glucose tolerance, increased creatinine clearance, and inhibition of gonadotrophin secretion.
Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea.
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests - AST/ALT
Prostatic specific antigen - PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult males: 10 - 30mg taken orally per day in divided doses for a duration of 3 to 6 weeks.
10mg uncoated tablets: 100 tablets per bottle or 100 tablets in blisters.
Protect from light. Store at 15 - 25oC.
PRODUCT AUTHENTICATION :
NEWS / EVENTS
Magnum Pharmaceuticals Authentication
Try our new method to quickly authenticate your product using the 2D barcode.
Click the respective link to download the QR Reader app for your phone.
Please Note : We do not sell or ship to the USA, Europe, Australia or any other locations where prohibited. All information contained within this website or in any literature provided is not a prescription to use. Please seek the advice of a physician specializing in Andrology before use.
Not affiliated with Magnum Pharma (USA), Magnum Pharmaceuticals Inc. (USA), Magnum Chemi-Tech Ltd., or Magnum Nutraceuticals (Asia) Pte Ltd.
Distributors must submit licensing, a company profile, and our completed distributor application for approval prior to ordering.